The PCSK9 gene (proprotein convertase subtilisin/kexin type 9) contains instructions for producing a protein that plays a major role in regulating cholesterol levels in the bloodstream. This gene is located on chromosome 1. The PCSK9 protein works by breaking down low-density lipoprotein (LDL) receptors on liver cells, which reduces the liver’s ability to remove LDL cholesterol from the blood. When PCSK9 activity is elevated, cholesterol levels rise; therefore, blocking this protein has become an important therapeutic strategy for lowering cholesterol.
Key Aspects of the PCSK9 Gene
Function:
The PCSK9 protein regulates how many LDL receptors are present on liver cells. These receptors remove LDL (“bad”) cholesterol from circulation, so fewer receptors lead to higher LDL levels in the bloodstream.
Genetic Effects:
- Gain-of-function mutations: These mutations cause the protein to become overactive, destroying too many LDL receptors. This results in familial hypercholesterolemia, a condition characterized by very high LDL cholesterol.
- Loss-of-function mutations: These reduce PCSK9 activity, leaving more LDL receptors available. As a result, LDL levels drop and the risk of cardiovascular disease decreases.
Therapeutic Targeting (PCSK9 Inhibitors):
Medications such as Praluent (alirocumab) and Repatha (evolocumab) are FDA-approved PCSK9 inhibitors. These drugs block the PCSK9 protein and can lower LDL cholesterol by approximately 50%–60%. They are typically given as injections to individuals with high cholesterol or those requiring additional LDL reduction. PCSK9 inhibitors are especially effective for patients with familial hypercholesterolemia or for those who cannot tolerate statins.
Loss-of-function mutations in the PCSK9 gene can act like a biological “superpower” because they significantly lower LDL cholesterol (the so-called “bad” cholesterol) from birth. Individuals who carry these rare variants often have dramatically reduced lifetime LDL-C levels, which can translate into as much as an 88% lower risk of cardiovascular disease. This protective effect is linked to improved recycling of LDL receptors, allowing the body to remove more cholesterol from the bloodstream and supporting long-term heart health and longevity.
Key Aspects of the PCSK9 “Superpower”
Remarkably Low Cholesterol:
People with loss-of-function mutations produce less active PCSK9 protein. As a result, more LDL receptors remain available on liver cells, leading to consistently low LDL cholesterol throughout life and reduced plaque buildup in arteries.
Reduced Cardiovascular Risk:
This lifelong reduction in LDL levels is associated with a dramatic decrease in the risk of heart disease—reported in some studies to be as high as 88%.
Mechanism of Action:
Under normal conditions, PCSK9 binds to LDL receptors in the liver and promotes their breakdown. When PCSK9 is inactive or reduced, these receptors are preserved and recycled, enabling the liver to clear greater amounts of LDL cholesterol from the blood.
Disease Resistance:
Beyond cardiovascular protection, some research suggests that these protective variants may also be linked to lower susceptibility to certain infections and potential protection against liver disease.
Therapeutic Application
PCSK9 Inhibitors:
Researchers have used this natural advantage to develop therapies that mimic the effect. Antibody-based drugs and small interfering RNA (siRNA) treatments block PCSK9 activity, helping patients with high cholesterol achieve substantial LDL reductions.
Potent Combination Therapy:
When combined with statins, PCSK9-targeting therapies can further reduce LDL cholesterol—often by an additional 60%—particularly in individuals at high cardiovascular risk.
The Other Side of the Coin
Gain-of-Function Mutations:
In contrast, gain-of-function mutations in the PCSK9 gene cause excessive destruction of LDL receptors. This leads to familial hypercholesterolemia, a condition characterized by dangerously high cholesterol levels from an early age and a significantly increased risk of cardiovascular disease.
This contrast highlights how PCSK9 activity plays a central role in cholesterol regulation—where reduced activity provides strong protection, while increased activity can contribute to serious health risks.
Plasma PCSK9 levels were found to be significantly higher among African Americans compared to Caucasians, higher in females than males, and elevated in adults relative to children. Overall, PCSK9 concentrations were not linked to total plasma Lp(a) levels when examining the entire participant group or when analyzed by ethnicity. However, PCSK9 showed a significant positive relationship with isoform-specific Lp(a) levels associated with larger apo(a) sizes across all participants.
This association was particularly evident among African Americans but not among Caucasians. No meaningful associations were observed between PCSK9 and isoform-specific Lp(a) levels linked to smaller apo(a) sizes. Heritability analyses also demonstrated that PCSK9 levels are genetically influenced in both groups, with stronger heritability estimates in Caucasians compared to African Americans.
These findings indicate that, among African Americans, PCSK9 levels are connected to isoform-specific Lp(a) carried on larger apo(a) sizes, whereas this relationship is absent in Caucasians. This highlights a distinct ethnic variation in how PCSK9 interacts with isoform-specific Lp(a) levels.
PCSK9 inhibition using monoclonal antibodies is an effective therapy for lowering LDL cholesterol by enhancing LDL receptor activity. Clinical studies have shown that this approach substantially reduces LDL-C levels across diverse patient populations and also decreases the risk of atherosclerotic and recurrent ischemic cardiovascular events. In addition to lowering LDL-C, PCSK9 inhibitors have been shown to reduce Lp(a) levels, although the exact mechanism behind this effect remains unclear.
Lp(a) consists of an LDL-like particle where apolipoprotein B-100 is linked to apolipoprotein(a), a protein characterized by a variable number of repeated kringle structures. Genetic variation in apo(a) strongly influences Lp(a) concentrations, and elevated Lp(a) levels—often associated with fewer kringle repeats—are recognized as an independent risk factor for cardiovascular disease. Research suggests that the interaction between PCSK9 and Lp(a) may depend on the apoB component of Lp(a). Interestingly, while both statins and PCSK9 inhibitors increase LDL receptor activity and lower LDL-C, they produce opposite effects on Lp(a), emphasizing the need to better understand the relationship between PCSK9 and Lp(a).
This study explored the association between circulating PCSK9 levels and Lp(a) in a healthy population that included both children and adults from African American and Caucasian backgrounds. By analyzing isoform-specific Lp(a) levels and considering genetic and phenotypic differences in apo(a), the research aimed to clarify whether PCSK9 is positively associated with isoform-specific Lp(a), particularly in African Americans.
.jpg)
.jpg)